Yong Qing Luo
Chief Executive Officer at EVEREST MEDICINES LIMITED
Net worth: 3 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Zhi Hong | M | 60 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. Pharmaceuticals: MajorHealth Technology Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China. | 6 years |
Ian Ying Woo | M | 51 | 6 years | |
Hui Tang | F | 64 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | 3 years |
Gregg Alton | M | 58 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | 3 years |
Martin Murphy | M | 81 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | 3 years |
Yiu Wa Tsui | M | 74 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | 3 years |
Xu Xin Liu | F | 40 | 3 years | |
Hoi Yam Chui | F | 57 | 1 years | |
Axel Bouchon | M | 52 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | 2 years |
Karen D. Neuendorff | M | 49 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | 2 years |
Yi Fan Li | M | 55 | 4 years | |
Robert Nelsen | M | 60 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. Pharmaceuticals: MajorHealth Technology Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China. | 6 years |
Tai Yin Yang | M | 70 | 2 years | |
Shi Dong Jiang | M | 57 | 4 years | |
Jing Yang | F | - | 2 years | |
Yang Shi | F | 48 | 5 years | |
Groot Eleanor de | M | - |
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. Pharmaceuticals: MajorHealth Technology Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China. | - |
Michael Berry | M | 59 | 1 years | |
Jennifer Yang | M | 56 | 3 years | |
An Kang Li | M | 47 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | - |
Li Yan | M | 57 |
Brii Biosciences Ltd.
Brii Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Brii Biosciences Ltd. is a biotechnology company, which engages in the provision of healthcare solutions. It focuses on the development of therapies for infectious diseases such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The company was founded by Zhi Hong in 2018 and is headquartered in Durham, NC. | - |
Skuban Aleksandar | M | - |
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. Pharmaceuticals: MajorHealth Technology Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China. | - |
Eric Rowinsky | M | 67 | 7 years | |
Zhengying Zhu | M | 51 | 7 years | |
Xu Zhu | F | 54 | 7 years | |
Susannah Cantrell | M | - | 2 years | |
Ki Chul Cho | M | 46 | - | |
Wei Fu | M | 42 | 7 years | |
Yee Wa Lau | F | 52 | - | |
Hong Chow | M | 53 |
Shanghai Roche Pharmaceuticals Ltd.
Shanghai Roche Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Shanghai Roche Pharmaceuticals Ltd. is a Chinese company that develops, manufactures, and distributes anti-cancer and virus drugs. The company is based in Shenchang, China. | 9 years |
Honggang Feng | M | 59 | - | |
Yi Min Zhang | M | 70 |
China Europe International Business School
| 20 years |
Ding Bo Xu | M | 62 |
China Europe International Business School
| 20 years |
Wing Tsz Ho | F | 54 | 3 years | |
Jason M. Brown | M | 52 | 7 years | |
Eleanor de Groot | M | 55 | 2 years | |
Lin Ni | F | - |
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. Pharmaceuticals: MajorHealth Technology Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ann Marie Fudge | F | 72 | - | |
Xinhui Hu | M | 51 | 5 years | |
Hong Zhao | M | 60 |
Beijing Novartis Pharma Ltd.
Beijing Novartis Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Beijing Novartis Pharma Ltd. is a pharmaceutical company. The company is based in Beijing, China. Founded in 1987, it operates in the pharmaceutical industry. | 16 years |
Bo Tan | M | 51 | 3 years | |
Xiaofan Zhang | M | 40 | 6 years | |
William Brody | M | 80 | - | |
Lin Long Yao | M | 60 |
China Europe International Business School
| 2 years |
Shu Guang Liu | M | 55 |
China Europe International Business School
| 2 years |
Ran Ting Qian | F | 49 |
China Europe International Business School
| 2 years |
Keung Lee | M | 56 |
China Europe International Business School
| 2 years |
Xiang Rong Li | F | 51 |
China Europe International Business School
| 2 years |
Yang Jing Li | M | 51 |
China Europe International Business School
| 2 years |
Wei Li | M | 58 |
China Europe International Business School
| 2 years |
Jun Long Huang | M | 59 |
China Europe International Business School
| 2 years |
Kun Zong Wu | M | 53 |
China Europe International Business School
| 2 years |
Jun Liu | M | 63 |
China Europe International Business School
| 2 years |
Hong Yan Shen | F | 53 |
China Europe International Business School
| 2 years |
Shao-Tong Bai | M | 60 |
China Europe International Business School
| 2 years |
Qiang Li | M | 56 |
China Europe International Business School
| 2 years |
Warren Wang | M | - |
China Europe International Business School
| 2 years |
Feng Qi | M | 54 |
China Europe International Business School
| 2 years |
Xiao Yan Hu | F | 52 |
China Europe International Business School
| 2 years |
Xiao Ou Zhang | M | 51 |
China Europe International Business School
| 2 years |
Jing Bo Liu | M | 62 |
China Europe International Business School
| 2 years |
Dong Sheng Xu | M | - |
China Europe International Business School
| 2 years |
Hong Zhao | F | 54 |
China Europe International Business School
| 2 years |
Yong Liu | M | 57 |
China Europe International Business School
| 2 years |
Hao Wang | M | 56 |
China Europe International Business School
| 2 years |
Jia He | M | 70 |
China Europe International Business School
| 3 years |
Arthur Yu Chen | M | 48 |
China Europe International Business School
| 2 years |
Quan Hong Yuan | M | 50 |
China Europe International Business School
| 2 years |
Xiong Hu | M | 52 |
China Europe International Business School
| 2 years |
Xiao Yan Sun | F | 52 |
China Europe International Business School
| 2 years |
Dong Li | M | 64 |
China Europe International Business School
| 3 years |
Yabo Zhang | M | 50 |
China Europe International Business School
| 2 years |
Hai Long Zhu | M | 56 |
China Europe International Business School
| - |
Wei Yao Wang | M | 61 |
China Europe International Business School
| 2 years |
Li Qing Zeng | M | 54 |
China Europe International Business School
| 2 years |
Jing Lou | M | 61 |
China Europe International Business School
| 2 years |
Jian Zhu | M | 49 |
China Europe International Business School
| 2 years |
Lai Suo Li | M | 63 |
China Europe International Business School
| 2 years |
Ding Wu | M | 59 |
China Europe International Business School
| 2 years |
Lu Yun Zhang | F | 63 |
China Europe International Business School
| 2 years |
Yu Feng Chi | M | 53 |
China Europe International Business School
| 2 years |
Jian Chao Yu | M | 56 |
China Europe International Business School
| 2 years |
Ming Gui Zou | M | 60 |
China Europe International Business School
| 2 years |
Zong Min Wu | M | 58 |
China Europe International Business School
| 2 years |
Fang Zhu | F | 54 |
China Europe International Business School
| 2 years |
Bing Wang | M | 52 |
China Europe International Business School
| 2 years |
Li Cheng Jiang | M | 66 |
China Europe International Business School
| 2 years |
Qi Yu Chen | M | 52 |
China Europe International Business School
| 2 years |
Hong Ning Sun | M | 63 |
China Europe International Business School
| 2 years |
Weimin Yin | M | 52 |
China Europe International Business School
| 2 years |
Hong Yan | M | 57 |
China Europe International Business School
| 2 years |
Wei Dong Shi | M | 57 |
China Europe International Business School
| 2 years |
Jian Zhong | M | 53 |
China Europe International Business School
| 2 years |
Cao He | M | 69 |
China Europe International Business School
| 2 years |
Jun Mo | M | 57 |
China Europe International Business School
| 2 years |
Ping Chen | M | 59 |
China Europe International Business School
| 2 years |
Zeng Gen Zhang | M | 59 |
China Europe International Business School
| 2 years |
Xin Li | M | 54 |
China Europe International Business School
| 2 years |
Zhi Qiang Wang | M | 67 |
China Europe International Business School
| 2 years |
Mian Huan Li | M | 54 |
China Europe International Business School
| 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
China | 66 | 66.00% |
Cayman Islands | 30 | 30.00% |
United States | 10 | 10.00% |
Switzerland | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Yong Qing Luo
- Personal Network